EGFR抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用技术

本发明专利技术公开了EGFR抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用。具体涉及N‑(5‑((4‑(1‑环丙基‑1H‑吲哚‑3‑基)嘧啶‑2‑基)氨基)‑2‑((2‑(二甲氨基)乙基)(甲基)氨基)‑4‑甲氧苯基)丙烯酰基酰胺游离碱或其酸式盐的多晶型和其制备方法，以及所述的多晶型在制备治疗EGFR突变体活性介导疾病药物中的应用，用于抑制L858R EGFR突变体、T790M EGFR突变体和外显子19缺失激活突变体等的活性，可广泛应用于预防与治疗癌症尤其是非小细胞肺癌等相关疾病，有望开发成新一代EGFR抑制剂。

Polymorphism, preparation method and application of free base or acid salt of EGFR inhibitor

The invention discloses polymorphism of free base or acid salt of EGFR inhibitor, preparation method and application thereof. Specifically involving polycrystalline forms and preparation methods of N(5) (4 ((4 (1 (1 (4 (1 (1) cyclopropyl 1H indindole 3 -yl) pyrimrimrimine 2 amino amino) amino)8209 ((2 (dimethylamino) ethyl (methylamino)8209;4 methoxyphenyl) acrylamiamiamide free base or its acid form salts, polycrystalline forms and their preparation methods, and the polycrystalline forms of the polycrystalline forms and their acid salts, and The results of this study are as follows:1. The application of disease drugs can inhibit the activity of L858R EGFR mutant, T790M EGFR mutant and exon 19 deletion activation mutant. It can be widely used in the prevention and treatment of cancer, especially non-small cell lung cancer and other related diseases. It is expected to develop a new generation of EGFR inhibitors.

【技术实现步骤摘要】
【国外来华专利技术】PCT国内申请，说明书已公开。

【技术保护点】
PCT国内申请，权利要求书已公开。

【技术特征摘要】
【国外来华专利技术】2016.03....

【专利技术属性】
技术研发人员：陈中科，刘福萍，刘磊，包如迪，
申请(专利权)人：江苏豪森药业集团有限公司，上海翰森生物医药科技有限公司，
类型：发明
国别省市：江苏,32